PuSH - Publikationsserver des Helmholtz Zentrums München

Früherkennung und Primärprävention des Typ-1-Diabetes: „Global Platform for the Prevention of Autoimmune Diabetes“ (GPPAD).

Early detection and primary prevention of type 1 diabetes: Global Platform for the Prevention of Autoimmune Diabetes (GPPAD).

Diabetologe 14, 240-244 (2018)
Postprint DOI
Open Access Green
Background: Betacell autoimmunity, which leads to type 1 diabetes, starts in early childhood with a peak in incidence at 12 months and insulin is its primary target. GPPAD (Global Platform for the Prevention of Autoimmune Diabetes): This network of collaborating European scientists aims to realize the early detection of an elevated risk to develop type 1 diabetes and primary prevention of betacell autoimmunity and type 1 diabetes in Europe. A new genetic risk score can identify newborns with 25-fold increased risk of type 1 diabetes. These children can participate in a primary prevention trial called POInT (Primary Oral Insulin Trial). POInT study: This is a randomized, placebo-controlled, double-blind clinical trial that will test the efficacy of oral insulin to prevent autoimmunity and type 1 diabetes.
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Autoimmune Diabetes ; Genetic Predisposition To Disease ; Genetic Testing ; Infant, Newborn ; Insulin; Cell-line Thp-1; In-vitro; Hacat Keratinocytes; Alkaloid Berberine; Dendritic Cells; Injury; Skin; Sensitization; Expression; Toxicity
ISSN (print) / ISBN 1860-9716
e-ISSN 1860-9724
Zeitschrift Diabetologe, Der
Quellenangaben Band: 14, Heft: 4, Seiten: 240-244 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort Elsevier House, Brookvale Plaza, East Park Shannon, Co, Clare, 00000, Ireland
Begutachtungsstatus Peer reviewed